Hairy cell leukaemia (HCL) presenting during pregnancy is an uncommon situation. Only a limited number of cases have been reported in the literature, making evidence-based guidance especially valuable in this setting.
The concurrent management of a haematological malignancy and an ongoing pregnancy requires careful consideration of treatment safety for both the mother and the developing fetus.
When treatment is indicated, the choice of agent is guided primarily by the comparative safety profile for both mother and fetus. A specific type of immunomodulatory therapy has been identified as the treatment of choice in this context on the basis of its tolerability and outcomes data.
DOI: 10.1093/annonc/mdv200
Only a few cases of HCL during pregnancy have been reported [52, 53].
If treatment is indicated, the lower risks associated with IFN-α for both the mother and the fetus make it the treatment of choice [V, B].
IFN-α shows good tolerance, uncomplicated pregnancy and delivery, and normal child development [54].
View source ↗